A retrospective review of a community-based practice provides insights into navigating setbacks in IBD care initiation due to insurance requirements.

A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.

Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.

Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.

A study revealed using language models as diagnostic aids did not significantly enhance clinical reasoning or accuracy among physicians over conventional resources alone.

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

Murina highlighted takeaways from her seminar-in-depth regarding the evolving therapeutic landscape of HS.

The FDA originally issued a CRL requesting additional CMC data in April 2024.

At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.

A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.

In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’

Data from ACG 2024 show only 1 in 12 patients eligible for second-line PBC therapy are actually doing receiving it—and it may take up to a year to initiate.

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

ChatGPT may provide helpful information around gastroparesis, IBS and celiac disease diets, according to findings from a new study.

Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.

This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.

Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.